InVisionSeq™ is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients. It is available world-wide for both commercial and research use for a range of cancer types. This test is not reimbursed in the US.
Acute Myelogenous Leukemia, Bladder Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colon Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Glioblastoma, Glioma, Head and Neck Cancer, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Mantle Cell Lymphoma, Melanoma, Myelodysplastic Syndrome, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pituitary Gland Carcinoma, Prostate Cancer, Testicular Cancer, Thyroid Gland Papillary Carcinoma, Uterine Cancer
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), CCND1 (Cyclin D1), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...